Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2018 16:01 ET | Source: Endocyte, Inc.

Endocyte Announces Presentations at the CAR-TCR Summit 2018

WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
August 17, 2018 08:30 ET | Source: Endocyte, Inc.

Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition

WEST LAFAYETTE, Ind., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
August 08, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference

WEST LAFAYETTE, Ind., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
July 31, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte Provides Second Quarter 2018 Financial Results and Operational Update

-Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035- -Investigational new drug (IND)...
July 25, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call

WEST LAFAYETTE, Ind., July 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
July 09, 2018 08:00 ET | Source: Endocyte, Inc.

Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group of...
June 26, 2018 19:00 ET | Source: Endocyte, Inc.

Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year

WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
June 25, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte to Join the Russell 3000® Index

WEST LAFAYETTE, Ind., June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
June 22, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

WEST LAFAYETTE, Ind., June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...
June 05, 2018 08:01 ET | Source: Endocyte, Inc.

Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer

WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced...